← Back to Screener
EDAP TMS SA (EDAP)
Price$3.59
Favorite Metrics
Price vs S&P 500 (26W)55.29%
Price vs S&P 500 (4W)-16.03%
Market Capitalization$155.40M
All Metrics
Book Value / Share (Quarterly)$0.73
P/TBV (Annual)1.75x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.20%
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)4.35%
Gross Margin (TTM)42.52%
Net Profit Margin (TTM)-40.68%
EPS (TTM)$-0.62
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.62
Revenue Growth (5Y)9.05%
EPS (Annual)$-0.60
ROI (Annual)-36.38%
Gross Margin (Annual)40.40%
Net Profit Margin (5Y Avg)-7.90%
Cash / Share (Quarterly)$0.33
Revenue Growth QoQ (YoY)24.76%
ROA (Last FY)-22.10%
Revenue Growth TTM (YoY)9.65%
EBITD / Share (TTM)$-0.64
ROE (5Y Avg)-18.58%
Operating Margin (TTM)-38.39%
Cash Flow / Share (Annual)$-0.56
P/B Ratio4.81x
P/B Ratio (Quarterly)3.12x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.47x
Net Interest Coverage (TTM)-27.52x
ROA (TTM)-27.00%
EV / EBITDA (TTM)86.05x
EPS Incl Extra (Annual)$-0.60
Current Ratio (Annual)1.85x
Quick Ratio (Quarterly)0.97x
3-Month Avg Trading Volume0.06M
52-Week Price Return155.07%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.25
P/S Ratio (Annual)1.85x
Asset Turnover (Annual)0.66x
52-Week High$5.05
Operating Margin (5Y Avg)-7.64%
EPS Excl Extra (Annual)$-0.60
CapEx CAGR (5Y)55.57%
Tangible BV CAGR (5Y)8.40%
26-Week Price Return59.28%
Quick Ratio (Annual)1.33x
13-Week Price Return-14.15%
Total Debt / Equity (Annual)0.28x
Current Ratio (Quarterly)1.41x
Enterprise Value$126.683
Revenue / Share Growth (5Y)3.87%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)3.04%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.24x
Pretax Margin (Annual)-33.98%
Cash / Share (Annual)$0.94
3-Month Return Std Dev71.77%
Gross Margin (5Y Avg)43.39%
Net Income / Employee (TTM)$-0
ROE (Last FY)-46.50%
Net Interest Coverage (Annual)-8.18x
EPS Basic Excl Extra (Annual)$-0.60
P/FCF (TTM)19.59x
Receivables Turnover (TTM)2.47x
Total Debt / Equity (Quarterly)0.26x
EPS Incl Extra (TTM)$-0.62
Receivables Turnover (Annual)3.87x
ROI (TTM)-49.54%
P/S Ratio (TTM)2.58x
Pretax Margin (5Y Avg)-6.75%
Revenue / Share (Annual)$1.92
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)125.24%
Year-to-Date Return6.99%
5-Day Price Return4.76%
EPS Normalized (Annual)$-0.60
ROA (5Y Avg)-10.06%
Net Profit Margin (Annual)-35.05%
Month-to-Date Return-5.38%
EBITD / Share (Annual)$-0.57
Operating Margin (Annual)-32.79%
LT Debt / Equity (Annual)0.05x
ROI (5Y Avg)-15.39%
LT Debt / Equity (Quarterly)0.04x
EPS Basic Excl Extra (TTM)$-0.62
P/TBV (Quarterly)1.75x
P/B Ratio (Annual)1.70x
Inventory Turnover (TTM)2.08x
Pretax Margin (TTM)-39.91%
Book Value / Share (Annual)$1.29
Price vs S&P 500 (13W)-14.83%
Beta-0.03x
P/FCF (Annual)28.30x
Revenue / Share (TTM)$1.37
ROE (TTM)-62.07%
52-Week Low$1.21
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
EDAPEDAP TMS SA | 2.58x | 9.05% | 42.52% | -38.39% | $3.59 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.65 |
MASIMasimo Corporation | 6.12x | 5.95% | 61.90% | 20.30% | $178.29 |
TMDXTransMedics Group, Inc. Common Stock | 6.58x | 88.21% | 59.92% | 17.93% | $109.12 |
LIVNLivaNova PLC Ordinary Shares | 2.56x | 8.24% | 68.04% | 14.09% | $65.01 |
ITGRInteger Holdings Corporation | 1.63x | 11.55% | 27.39% | 11.90% | $88.37 |
AXGNAxogen, Inc. Common Stock | 7.92x | 14.93% | 74.31% | -3.49% | $37.37 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $37.91 |
BLFSBioLife Solutions Inc. | 10.59x | 14.87% | 64.56% | -17.26% | $20.85 |
INMDInMode Ltd. Ordinary Shares | 2.45x | 12.45% | 78.54% | 23.05% | $14.33 |
CBLLCeriBell, Inc. Common Stock | 8.68x | — | 87.89% | -65.57% | $20.74 |
About
Edap TMS SA develops and markets ultrasound-based medical devices for urology and oncology, with three core divisions: HIFU technology for minimally invasive tumor treatment, ESWL systems for kidney stone lithotripsy, and a distribution channel for complementary medical products. The company generates revenue from both proprietary device sales and service of its global installed base across North America, Europe, and Asia.